AstraZeneca stock falls after FDA panel votes against new cancer drug - CNBC
Source:CNBC
The advisory panel wasn’t convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
Related Articles
Amazon’s Andy Jassy bets on $200bn AI spending drive to revive AWS - Financial Times
Shake-up follows fears tech giant missed early AI boom as Microsoft and Google challenge cloud …
Asia stocks fall as rate uncertainty, Iran tensions weigh; S.Korea outperforms - Investing.com
Asia stocks fall as rate uncertainty, Iran tensions weigh; S.Korea outperforms
Canada’s Tariff Cut Just Made This High-Tech Chinese EV 50% Cheaper - InsideEVs
A high-end electric performance SUV that’s made in China is about to get dramatically cheaper …
A Winner in Early Trump Tariffs, Vietnam Thrives in Trade War 2.0 - bloomberg.com
A year on from “Liberation Day”, Trump’s tariffs have fueled a change in global supply chains — just …